Investigational Drug Information for Defactinib
✉ Email this page to a colleague
What is the development status for investigational drug Defactinib?
Defactinib is an investigational drug.
There have been 27 clinical trials for Defactinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 18th 2024.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Pancreatic Neoplasms. The leading clinical trial sponsors are Verastem, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.
There are twelve US patents protecting this investigational drug and one hundred and seventy-seven international patents.
Summary for Defactinib
| US Patents | 12 |
| International Patents | 177 |
| US Patent Applications | 127 |
| WIPO Patent Applications | 103 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 2 (2024-03-18) |
| Vendors | 54 |
Recent Clinical Trials for Defactinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | European Network of Gynaecological Oncological Trial Groups (ENGOT) | Phase 3 |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | GOG Foundation | Phase 3 |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Verastem, Inc. | Phase 3 |
Clinical Trial Summary for Defactinib
Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib
US Patents for Defactinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Defactinib | ⤷ Sign Up | Methods of diagnosing and treating B cell acute lymphoblastic leukemia | The General Hospital Corporation (Boston, MA) Tufts Medical Center, Inc. (Boston, MA) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | Methods and compositions for treating abnormal cell growth | Verastem, Inc. (Needham, MA) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | Sulfonyl amide derivatives for the treatment of abnormal cell growth | Pfizer, Inc. (New York, NY) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | Inhibitors of immune checkpoint modulators and related methods | eFFECTOR Therapeutics Inc. (San Diego, CA) | ⤷ Sign Up |
| Defactinib | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Defactinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Defactinib | World Intellectual Property Organization (WIPO) | WO2015054477 | 2033-10-09 | ⤷ Sign Up |
| Defactinib | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Defactinib | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Defactinib | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Defactinib | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Defactinib | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Defactinib | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
